LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Compugen Ltd

Uždarymo kaina

1.65 0.61

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.57

Max

1.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.1M

-7.2M

Pardavimai

813K

2.3M

P/E

Sektoriaus vid.

60.333

50.291

Pelnas, tenkantis vienai akcijai

-0.08

Pelno marža

-314.405

Darbuotojai

74

EBITDA

-12M

-7.5M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+329.45% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-534M

152M

Ankstesnė atidarymo kaina

1.04

Ankstesnė uždarymo kaina

1.65

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-27 20:51; UTC

Uždarbis

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 20:48; UTC

Rinkos pokalbiai

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025-06-27 20:46; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-27 20:46; UTC

Rinkos pokalbiai

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025-06-27 19:31; UTC

Rinkos pokalbiai

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025-06-27 19:19; UTC

Rinkos pokalbiai

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025-06-27 19:16; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:57; UTC

Įsigijimai, susijungimai, perėmimai

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025-06-27 18:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-27 18:42; UTC

Rinkos pokalbiai

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025-06-27 18:39; UTC

Rinkos pokalbiai
Uždarbis

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025-06-27 18:29; UTC

Rinkos pokalbiai

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025-06-27 18:18; UTC

Rinkos pokalbiai

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025-06-27 18:16; UTC

Rinkos pokalbiai

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025-06-27 17:16; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025-06-27 17:08; UTC

Uždarbis

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025-06-27 16:52; UTC

Įsigijimai, susijungimai, perėmimai

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025-06-27 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025-06-27 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-27 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-27 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-27 15:59; UTC

Rinkos pokalbiai

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025-06-27 15:56; UTC

Rinkos pokalbiai

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

329.45% į viršų

12 mėnesių prognozė

Vidutinis 7 USD  329.45%

Aukščiausias 10 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.